Maritech fucoidan ingredients are the first and only high-purity fucoidan extracts to achieve GRAS status, says the company.
Photo © iStockphoto.com/BryanToro
A biotechnology company called Marinova Pty. Ltd. (Tasmania, Australia) announced that its proprietary fucoidan extract is now Generally Recognized as Safe (GRAS) by FDA. Maritech fucoidan ingredients are the first and only high-purity fucoidan extracts to achieve GRAS status, says the company.
The FDA responded “no questions” to findings by an independent panel of experts. The panel determined that the fucoidan extracts from two species of seaweed-Undaria pinnatifida and Fucus vesiculosus-are safe for use as a food ingredient in dosages of up to 250 mg per day. Fucoidan is a bioactive polysaccharide that occurs naturally in brown seaweed, and the company says that its fucoidan extracts have been shown to support immune and digestive health, possess antiaging properties, and may aid in tumor suppression, anti-inflammation, and viral inhibition.
“GRAS recognition is testament to the safety and quality of Maritech fucoidan extracts, giving our customers even further confidence that they are getting the highest quality and most effective fucoidan ingredients on the market,” said Damien Stringer, PhD, operations manager, Marinova, in a press release.
The company notes that this GRAS status achievement follows previous regulatory accreditations in such markets as Australia, Canada, Europe, and China, among others. The extracts have also been granted non-GMO, Kosher, and Halal certifications.
Also read:
FDA revokes authorization to use Red No. 3 as a color additive in food or drugs
January 15th 2025FDA contends that the color additive is safe for humans but is legally obligated by the Delaney Clause of the FD&C act to revoke authorization as research shows the Red No. 3 induces cancer in rats.
Magnesium L-threonate, Magtein, earns novel food authorization in the European Union
December 19th 2024According to the announcement, the authorization is also exclusive to AIDP and its partner company and licensee, ThreoTech, meaning that they are the only parties that can market magnesium L-threonate in the EU for a period of five years.